Biosenic SA

BioSenic appoints Michel Wurm, M.D. as Chief Medical Officer

02 Dec 2022 00:00:00 By Nasdaq GlobeNewswire

BioSenic SA: Transparency notifications received from François Rieger, Véronique Pomi, Capital Grand Est, FA DIESE 3 and CPH Banque

21 Nov 2022 00:00:00 By Nasdaq GlobeNewswire

BioSenic SA provides update on its autoimmune disease platform based on ATO (arsenic trioxide)

08 Nov 2022 00:00:00 By Nasdaq GlobeNewswire

BioSenic SA: Transparency notification received from S.R.I.W. SA and Sofipôle SA

04 Nov 2022 01:00:00 By Nasdaq GlobeNewswire

BioSenic SA : Information on the total number of voting rights and shares

03 Nov 2022 01:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics to start a new Euronext equity story with a change of name to BioSenic, following the acquisition of a majority participation of Medsenic valued at EUR 40 million

25 Oct 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics provides Third Quarter 2022 Business Update

21 Oct 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics to regain worldwide rights to ALLOB

07 Oct 2022 01:15:00 By Nasdaq GlobeNewswire

Bone Therapeutics to host Extraordinary General Meeting on 24 October 2022

06 Oct 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Information on the total number of voting rights and shares

30 Sep 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics reports half year 2022 results

07 Sep 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics to host Extraordinary General Meeting on 05 October 2022

05 Sep 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Information on the total number of voting rights and shares

31 Aug 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics to host Extraordinary General Meeting on 26 September 2022

26 Aug 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics to broaden and derisk therapeutic portfolio by acquiring majority participation in Medsenic

09 Aug 2022 17:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Information on the total number of voting rights and shares

29 Jul 2022 00:30:00 By Nasdaq GlobeNewswire

Bone Therapeutics optimizes statistical analysis and introduces interim analysis in the ongoing ALLOB Phase IIb study for high-risk tibial fractures

15 Jul 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics SA: Information on the total number of voting rights and shares

30 Jun 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics to host Extraordinary General Meeting on 13 July 2022

13 Jun 2022 00:00:00 By Nasdaq GlobeNewswire

Bone Therapeutics Provides First Quarter 2022 Business Update

01 Jun 2022 00:00:00 By Nasdaq GlobeNewswire